What is the half-life of ARA-290?

ARA-290 has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute ARA-290?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of ARA-290?

ARA-290 has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute ARA-290?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

ARA-290

Also known as: Cibinetide, Helix B Surface Peptide, HBSP

Overview

Key Facts

Primary Goal: Research and therapeutic applications of ARA-290

Activates the innate repair receptor (IRR/EPOR-βcR heterodimer). Suppresses pro-inflammatory cytokine release.

Dosing Information

Half-Life

~2 minutes (rapid clearance, prolonged tissue effects)

Typical Dose

2–4 mg

Frequency

1x daily

Cycle Length

4-12 weeks

Administration Routes:

subcutaneousintravenous

Benefits

Tissue protection and repair without EPO side effects
Reduces neuropathic pain in diabetic patients
Anti-inflammatory and anti-apoptotic properties
Improves small nerve fibre density
Promotes corneal nerve regeneration

Side Effects

Injection site reactions (mild)uncommonmild

Headache (uncommon)uncommonmild

Transient mild nauseauncommonmild

Mechanism of Action

Activates the innate repair receptor (IRR/EPOR-βcR heterodimer)

Suppresses pro-inflammatory cytokine release

Inhibits apoptosis in stressed tissues

Promotes Schwann cell and neurite migration

Does not bind the classical erythropoietin receptor

Contraindications

Do not use this peptide if any of the following apply:

Known hypersensitivity to erythropoietin-derived peptides
Pregnancy or breastfeeding
Active thromboembolic conditions

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration1 week

Research Summary

Preclinical

Multiple Phase 2 clinical trials completed for sarcoidosis-associated neuropathy and diabetic neuropathic pain. Demonstrated improved corneal nerve fibre density and reduced neuropathic symptoms. Developed by Araim Pharmaceuticals with promising safety and tolerability data.

Frequently Asked Questions

Common questions about ARA-290

UK-Specific Information

Exclusive data points and guidance for UK residents using ARA-290

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok